Reprint - Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction: A Cochrane Review

Cameron Edwin Alexander* (Corresponding Author), Malo MF Scullion, Muhammad Imran Omar, Yuhong Yuan, Charalampos Mamoulakis, James MO N'Dow, Changhao Chen, Thomas BL Lam

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

INTRODUCTION: There remains uncertainty regarding the differences in patient outcomes between monopolar transurethral resection of the prostate (MTURP) and bipolar TURP (BTURP) in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO).

METHODS: A systematic literature search was carried out up to March 19, 2019. Methods in the Cochrane Handbook were followed. Certainty of evidence (CoE) was assessed using the GRADE approach.

RESULTS: A total of 59 randomized controlled trials (RCTs) with 8924 participants were included. BTURP probably results in little to no difference in International Prostate Symptom Score (IPSS) at 12 months (mean difference -0.24, 95% confidence internal [CI] -0.39--0.09; participants=2531; RCTs=16; moderate CoE) or health-related quality of life (HRQOL) at 12 months (mean difference -0.12, 95% CI -0.25-0.02; participants=2004, RCTs=11; moderate CoE), compared to MTURP. BTURP probably reduces TUR syndrome (relative risk [RR] 0.17, 95% CI 0.09-0.30; participants= 6,745, RCTs=44; moderate CoE) and blood transfusions (RR 0.42, 95% CI 0.30-0.59; participants=5727, RCTs=38; moderate CoE), compared to MTURP. BTURP may carry similar risk of urinary incontinence at 12 months (RR 0.20, 95% CI 0.01-4.06; participants=751; RCTs=4; low CoE), re-TURP (RR 1.02, 95% CI 0.44-2.40; participants=652, RCTs=6, I 2=0%; low CoE) and erectile dysfunction (International Index of Erectile Function [IIEF-5]) at 12 months (mean difference 0.88, 95% CI -0.56-2.32; RCTs=3; moderate CoE), compared to MTURP.

CONCLUSIONS: BTURP and MTURP probably improve urological symptoms to a similar degree. BTURP probably reduces TUR syndrome and blood transfusion slightly postoperatively. The moderate certainty of evidence available for primary outcomes suggests no need for further RCTs comparing BTURP and MTURP.

Original languageEnglish
Pages (from-to)423-430
Number of pages8
JournalCanadian Urological Association Journal
Volume14
Issue number12
Early online date16 Jun 2020
DOIs
Publication statusPublished - Dec 2020

Bibliographical note

Acknowledgements: The authors would like to thank Professor Philipp Dahm, Coordinating Editor, Cochrane Urology, for his advice and guidance with regards to Cochrane review methodology. We are grateful to the following individuals for their kind efforts in assisting with study translation, assessment of eligibility and data extraction for foreign language articles: Lena Lantsova, Euan Fisher, Christopher Carroll, Sergio Fdez-Pello Montes, Jae Hung, Professor Phillipp Dahm.
Acknowledgement: This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2019, Issue 12, DOI: http://dx.doi.org/10.1002/14651858.CD009629.pub4 (see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review

Keywords

  • TURP Biopolar Monopolar

Fingerprint

Dive into the research topics of 'Reprint - Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction: A Cochrane Review'. Together they form a unique fingerprint.

Cite this